Clinical Trials Browser

Melanoma × lenvatinib × 1 year × Clear all

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT04889118 2025-12-23

LEAP-003

Phase 3 Completed

131 enrolled 16 charts

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT04207086 2025-12-16

Neo PeLe

Phase 2 Active not recruiting

21 enrolled

Dermatologic

Melanoma

NCT04955743 2025-11-24

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

Phase 2 Terminated

18 enrolled

CNSDermatologicGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell, Melanoma

NCT05282901 2025-11-24

PLUME

Phase 2 Active not recruiting

51 enrolled

Dermatologic

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT04700072 2025-10-28

KEYMAKER-U02

Phase 1/2 Completed

56 enrolled

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT05091346 2025-10-24

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

Phase 1/2 Completed

89 enrolled 24 charts

DermatologicGastrointestinal

Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms

NCT04305041 2025-08-29

KEYMAKER-U02

Phase 1/2 Completed

100 enrolled

Dermatologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT04305054 2025-08-29

KEYMAKER-U02

Phase 1/2 Active not recruiting

315 enrolled

Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT05308901 2025-07-25

Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma

Phase 2 Active not recruiting

6 enrolled 11 charts

Dermatologic

Uveal Melanoma, Melanoma